Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.

GIP GLP-1 receptor agonists Renal Tirzepatide

Journal

Endocrine

ISSN: 1559-0100

Titre abrégé: Endocrine

Pays: United States

ID NLM: 9434444

Informations de publication

Date de publication:
12 Mar 2024

Historique:

received: 11 11 2023

accepted: 18 02 2024

medline: 13 3 2024

pubmed: 13 3 2024

entrez: 13 3 2024

Statut: aheadofprint

Résumé

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management. The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects. This review aims to summarize the evidence regarding the nephroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) and tirzepatide and the putative mechanisms underlying the favorable renal profile of tirzepatide. A comprehensive literature search was performed from inception to July 31st 2023 to select research papers addressing the renal effects of GLP-1RA and tirzepatide. The pathogenesis of CKD in patients with T2D likely involves many contributors besides hyperglycemia, such as hypertension, obesity, insulin resistance and glomerular atherosclerosis, exerting kidney damage through metabolic, fibrotic, inflammatory, and hemodynamic mechanisms. Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels. Tirzepatide is likely to counteract most of the pathogenetic factors contributing to CKD in T2D, potentially representing a step forward in incretin-based therapy towards nephroprotection. Further evidence is needed to understand its role in renal hemodynamics, fibrosis, cell damage and atherosclerosis, as well as to conclusively show reduction of hard renal outcomes.

Identifiants

DOI: 10.1007/s12020-024-03757-9 PMID: 38472620

pubmed: 38472620

doi: 10.1007/s12020-024-03757-9

pii: 10.1007/s12020-024-03757-9

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

M.C. Thomas, M.E. Cooper, P. Zimmet, Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12, 73–81 (2016)

pubmed: 26553517 doi: 10.1038/nrneph.2015.173

H. Li, W. Lu, A. Wang, H. Jiang, J. Lyu, Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. J. Diabetes Investig. 12, 346–356 (2021)

pubmed: 32654341 doi: 10.1111/jdi.13355

J.L. Harding, M.E. Pavkov, D.J. Magliano, J.E. Shaw, E.W. Gregg, Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019)

pubmed: 30171279 doi: 10.1007/s00125-018-4711-2

R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Adler, R.R. Holman, UKPDS Study Group: risk factors for renal dysfunction in type 2 diabetes: U.K. Prospect. Diabetes Study 74. Diabetes 55, 1832–1839 (2006)

G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J. Hypertens. 29, 1802–1809 (2011)

pubmed: 21738053 doi: 10.1097/HJH.0b013e3283495cd6

R.Z. Alicic, E.J. Cox, J.J. Neumiller, K.R. Tuttle, Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227–244 (2021)

pubmed: 33219281 doi: 10.1038/s41581-020-00367-2

S. Zoungas, H. Arima, H.C. Gerstein, R.R. Holman, M. Woodward, P. Reaven et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 5, 431–437 (2017)

pubmed: 28365411 doi: 10.1016/S2213-8587(17)30104-3

I. Caruso, F. Giorgino, SGLT-2 inhibitors as cardio-renal protective agents. Metabolism 127, 154937 (2022)

pubmed: 34808144 doi: 10.1016/j.metabol.2021.154937

I. Caruso, A. Cignarelli, F. Giorgino, Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials. Trends Endocrinol. Metab. 30, 578–589 (2019)

pubmed: 31401015 doi: 10.1016/j.tem.2019.07.004

I. Caruso, A. Cignarelli, L. Laviola, F. Giorgino, GLP-1 receptor agonists for cardiovascular protection: a matter of time. Diabetes Care 45, e30–e31 (2022)

pubmed: 35020816 pmcid: 8914435 doi: 10.2337/dc21-1839

N. Sattar, M.M.Y. Lee, S.L. Kristensen, K.R.H. Branch, S. Del Prato, N.S. Khurmi et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9(10), 653–662 (2021)

pubmed: 34425083 doi: 10.1016/S2213-8587(21)00203-5

M.H.A. Muskiet, L. Tonneijck, Y. Huang, M. Liu, A. Saremi, H.J.L. Heerspink et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018)

pubmed: 30292589 doi: 10.1016/S2213-8587(18)30268-7

J.B. Buse, S.C. Bain, J.F.E. Mann, M.A. Nauck, S.E. Nissen, S. Pocock et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER Trial. Diabetes Care 43, 1546–1552 (2020)

pubmed: 32366578 pmcid: 7305014 doi: 10.2337/dc19-2251

F. Persson, S.C. Bain, O. Mosenzon, H.J.L. Heerspink, J.F.E. Mann, R. Pratley et al. Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER Trial. Diabetes Care 44, 1020–1026 (2021)

pubmed: 33504496 pmcid: 7985419 doi: 10.2337/dc20-1622

S.C. Tye, S.T. de Vries, J.F.E. Mann, M. Schechter, O. Mosenzon, P. Denig et al. Prediction of the effects of liraglutide on kidney and cardiovascular outcomes based on short-term changes in multiple risk markers. Front Pharm. 13, 786767 (2022)

doi: 10.3389/fphar.2022.786767

J.F.E. Mann, D.D. Ørsted, K. Brown-Frandsen, S.P. Marso, N.R. Poulter, S. Rasmussen et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017)

pubmed: 28854085 doi: 10.1056/NEJMoa1616011

J.F.E. Mann, T. Hansen, T. Idorn, L.A. Leiter, S.P. Marso, P. Rossing et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 8, 880–893 (2020)

pubmed: 32971040 doi: 10.1016/S2213-8587(20)30313-2

K.R. Tuttle, H. Bosch-Traberg, D.Z.I. Cherney, S. Hadjadj, J. Lawson, O. Mosenzon et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 103, 772–781 (2023)

pubmed: 36738891 doi: 10.1016/j.kint.2022.12.028

A.M. Shaman, S.C. Bain, G.L. Bakris, J.B. Buse, T. Idorn, K.W. Mahaffey et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145, 575–585 (2022)

pubmed: 34903039 doi: 10.1161/CIRCULATIONAHA.121.055459

H.C. Gerstein, H.M. Colhoun, G.R. Dagenais, R. Diaz, M. Lakshmanan, P. Pais et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019)

pubmed: 31189509 doi: 10.1016/S0140-6736(19)31150-X

O. Mosenzon, M. Schechter, G. Leibowitz, Kidney outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. Adv. Chronic Kidney Dis. 28, 347–360 (2021)

pubmed: 34922691 doi: 10.1053/j.ackd.2021.04.005

M.A. Bethel, R.J. Mentz, P. Merrill, J.B. Buse, J.C. Chan, S.G. Goodman et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes 67, 522–P (2018)

doi: 10.2337/db18-522-P

A.B. van der Aart-van der Beek, L.E. Clegg, R.C. Penland, D.W. Boulton, C.D. Sjöström, R.J. Mentz et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes. Metab. 22, 2493–2498 (2020)

pubmed: 32803900 pmcid: 7756541 doi: 10.1111/dom.14175

S. Yoshiji, H. Minamino, D. Tanaka, S. Yamane, N. Harada, N. Inagaki, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta-analysis and meta-regression analysis. Diabetes Obes. Metab. 24, 1029–1037 (2022)

pubmed: 35137511 doi: 10.1111/dom.14666

J.F.E. Mann, J.B. Buse, T. Idorn, L.A. Leiter, R.E. Pratley, S. Rasmussen et al. Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes Obes. Metab. 23, 2058–2066 (2021)

pubmed: 34009708 pmcid: 8453827 doi: 10.1111/dom.14443

D.K. McGuire, R.P. Busui, J. Deanfield, S.E. Inzucchi, J.F.E. Mann, N. Marx et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes. Metab. 25, 1932–1941 (2023)

pubmed: 36945734 doi: 10.1111/dom.15058

M.J. Davies, S.C. Bain, S.L. Atkin, P. Rossing, D. Scott, M.S. Shamkhalova et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39, 222–230 (2016)

pubmed: 26681713 doi: 10.2337/dc14-2883

L.A. Leiter, M.C. Carr, M. Stewart, A. Jones-Leone, R. Scott, F. Yang et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 37, 2723–2730 (2014)

pubmed: 25048383 doi: 10.2337/dc13-2855

O. Mosenzon, T.M. Blicher, S. Rosenlund, J.W. Eriksson, S. Heller, O.H. Hels et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 7, 515–527 (2019)

pubmed: 31189517 doi: 10.1016/S2213-8587(19)30192-5

K.R. Tuttle, M.C. Lakshmanan, B. Rayner, R.S. Busch, A.G. Zimmermann, D.B. Woodward et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018)

pubmed: 29910024 doi: 10.1016/S2213-8587(18)30104-9

P. Rossing, F.M.M. Baeres, G. Bakris, H. Bosch-Traberg, M. Gislum, S.C.L. Gough et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 38(9), 2041–2051 (2023)

doi: 10.1093/ndt/gfad009

I. Caruso, A. Cignarelli, G.P. Sorice, A. Natalicchio, S. Perrini, L. Laviola et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites 12(2), 183 (2022)

pubmed: 35208256 pmcid: 8879165 doi: 10.3390/metabo12020183

M. Rondinelli, A. Rossi, A. Gandolfi, F. Saponaro, L. Bucciarelli, G. Adda et al. Use of liraglutide in the real world and impact at 36 months on metabolic control, weight, lipid profile, blood pressure, heart rate, and renal function. Clin. Ther. 39, 159–169 (2017)

pubmed: 27939305 doi: 10.1016/j.clinthera.2016.11.001

B. Pasternak, V. Wintzell, B. Eliasson, A.-M. Svensson, S. Franzén, S. Gudbjörnsdottir et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43, 1326–1335 (2020)

pubmed: 32295809 doi: 10.2337/dc19-2088

M. Lugner, N. Sattar, M. Miftaraj, J. Ekelund, S. Franzén, A.-M. Svensson et al. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. 20, 67 (2021)

pubmed: 33752680 pmcid: 7983265 doi: 10.1186/s12933-021-01258-x

Y. Xie, B. Bowe, A.K. Gibson, J.B. McGill, G. Maddukuri, Y. Yan et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43, 2859–2869 (2020)

pubmed: 32938746 doi: 10.2337/dc20-1890

P. Ueda, V. Wintzell, E. Dahlqwist, B. Eliasson, A.-M. Svensson, S. Franzén et al. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study. Diabetes Obes. Metab. 24, 473–485 (2022)

pubmed: 34738703 doi: 10.1111/dom.14598

M. Baviera, A. Foresta, P. Colacioppo, G. Macaluso, M.C. Roncaglioni, M. Tettamanti et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol. 21, 162 (2022)

pubmed: 35999556 pmcid: 9400295 doi: 10.1186/s12933-022-01572-y

F.S. Willard, J.D. Douros, M.B. Gabe, A.D. Showalter, D.B. Wainscott, T.M. Suter, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 5(17) (2020)

D.J. Drucker, J.J. Holst, The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66(10), 1765–1779 (2023)

pubmed: 36976349 doi: 10.1007/s00125-023-05906-7

B. Sun, F.S. Willard, D. Feng, J. Alsina-Fernandez, Q. Chen, M. Vieth, Structural determinants of dual incretin receptor agonism by tirzepatide. Proc. Natl Acad. Sci. USA 119(13), e2116506119 (2022)

pubmed: 35333651 pmcid: 9060465 doi: 10.1073/pnas.2116506119

A. Novikoff, S.L. O’Brien, M. Bernecker, G. Grandl, M. Kleinert, P.J. Knerr et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol. Metab. 49, 101181 (2021)

pubmed: 33556643 pmcid: 7921015 doi: 10.1016/j.molmet.2021.101181

B. Jones, T. Buenaventura, N. Kanda, P. Chabosseau, B.M. Owen, R. Scott et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat. Commun. 9, 1602 (2018)

pubmed: 29686402 pmcid: 5913239 doi: 10.1038/s41467-018-03941-2

M. Lucey, P. Pickford, S. Bitsi, J. Minnion, J. Ungewiss, K. Schoeneberg et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol. Metab. 37, 100991 (2020)

pubmed: 32278079 pmcid: 7262448 doi: 10.1016/j.molmet.2020.100991

J.J. Meier, M.A. Nauck, D. Kranz, J.J. Holst, C.F. Deacon, D. Gaeckler et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654–662 (2004)

pubmed: 14988249 doi: 10.2337/diabetes.53.3.654

T. Idorn, F.K. Knop, M.B. Jørgensen, M. Christensen, J.J. Holst, M. Hornum et al. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. J. Clin. Endocrinol. Metab. 99, 2457–2466 (2014)

pubmed: 24712563 doi: 10.1210/jc.2013-3809

S. Urva, T. Quinlan, J. Landry, J. Martin, C. Loghin, Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin. Pharmacokinet. 60, 1049–1059 (2021)

pubmed: 33778934 pmcid: 8332596 doi: 10.1007/s40262-021-01012-2

S. Del Prato, S.E. Kahn, I. Pavo, G.J. Weerakkody, Z. Yang, J. Doupis et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398, 1811–1824 (2021)

pubmed: 34672967 doi: 10.1016/S0140-6736(21)02188-7

H.J.L. Heerspink, N. Sattar, I. Pavo, A. Haupt, K.L. Duffin, Z. Yang et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774–785 (2022)

pubmed: 36152639 doi: 10.1016/S2213-8587(22)00243-1

F.A. Holtkamp, D. de Zeeuw, M.C. Thomas, M.E. Cooper, P.A. de Graeff, H.J.L. Hillege et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 80, 282–287 (2011)

pubmed: 21451458 doi: 10.1038/ki.2011.79

M. Oshima, M.J. Jardine, R. Agarwal, G. Bakris, C.P. Cannon, D.M. Charytan et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 99, 999–1009 (2021)

pubmed: 33316282 doi: 10.1016/j.kint.2020.10.042

H.J.L. Heerspink, N. Sattar, I. Pavo, A. Haupt, K.L. Duffin, Z. Yang et al. Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis. Diabetes Care 46, 1501–1506 (2023)

pubmed: 37267479 pmcid: 10369133 doi: 10.2337/dc23-0261

M.C. Thomas, M. Brownlee, K. Susztak, K. Sharma, K.A.M. Jandeleit-Dahm, S. Zoungas et al. Diabetic kidney disease. Nat. Rev. Dis. Prim. 1, 15018 (2015)

pubmed: 27188921 doi: 10.1038/nrdp.2015.18

K.R. Tuttle, R. Agarwal, C.E. Alpers, G.L. Bakris, F.C. Brosius, P. Kolkhof et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102, 248–260 (2022)

pubmed: 35661785 doi: 10.1016/j.kint.2022.05.012

R. Agarwal. Pathogenesis of diabetic nephropathy. Chronic kidney disease and type 2 diabetes. (American Diabetes Association, Arlington (VA)), 2021)

R.Z. Alicic, J.J. Neumiller, K.R. Tuttle, Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 32, 377–385 (2023)

pubmed: 37195250 pmcid: 10241427 doi: 10.1097/MNH.0000000000000894

J. Skov, A. Dejgaard, J. Frøkiær, J.J. Holst, T. Jonassen, S. Rittig et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98, E664–71 (2013)

pubmed: 23463656 doi: 10.1210/jc.2012-3855

A. Asmar, P.K. Cramon, L. Simonsen, M. Asmar, C.M. Sorensen, S. Madsbad et al. Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man. J. Clin. Endocrinol. Metab. 104, 2509–2519 (2019)

pubmed: 30835273 doi: 10.1210/jc.2019-00004

S.C. Thomson, A. Kashkouli, Z.Z. Liu, P. Singh, Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin. Am. J. Physiol. Ren. Physiol. 313, F854–F858 (2017)

doi: 10.1152/ajprenal.00258.2017

F. Moschovaki Filippidou, A.H. Kirsch, M. Thelen, M. Kétszeri, K. Artinger, I. Aringer et al. Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation. Am. J. Pathol. 190, 400–411 (2020)

pubmed: 31759969 doi: 10.1016/j.ajpath.2019.10.008

M. Mazidi, E. Karimi, P. Rezaie, G.A. Ferns, Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J. Diabetes Complic. 31, 1237–1242 (2017)

doi: 10.1016/j.jdiacomp.2016.05.022

R. Hammoud, D.J. Drucker, Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201–216 (2023)

pubmed: 36509857 doi: 10.1038/s41574-022-00783-3

X. Gao, A. Lindqvist, M. Sandberg, L. Groop, N. Wierup, L. Jansson, Effects of GIP on regional blood flow during normoglycemia and hyperglycemia in anesthetized rats. Physiol. Rep. 6, e13685 (2018)

pubmed: 29673130 pmcid: 5907939 doi: 10.14814/phy2.13685

S.H. Hammoud, I. AlZaim, Y. Al-Dhaheri, A.H. Eid, A.F. El-Yazbi, Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases. Front. Endocrinol. 12, 707126 (2021)

doi: 10.3389/fendo.2021.707126

S. Ben-Shlomo, I. Zvibel, C. Varol, L. Spektor, A. Shlomai, E.M. Santo et al. Role of glucose-dependent insulinotropic polypeptide in adipose tissue inflammation of dipeptidylpeptidase 4-deficient rats. Obesity 21, 2331–2341 (2013)

pubmed: 23408696 doi: 10.1002/oby.20340

S.D. Pedersen, F. Giorgino, G. Umpierrez, V.T. Thieu, A. Rodríguez, C. Nicolay et al. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: a post hoc assessment of the SURPASS clinical trial programme. Diabetes Obes. Metab. 25, 2553–2560 (2023)

pubmed: 37246796 doi: 10.1111/dom.15140

J. Rosenstock, C. Wysham, J.P. Frías, S. Kaneko, C.J. Lee, L. Fernández Landó et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021)

pubmed: 34186022 doi: 10.1016/S0140-6736(21)01324-6

J.P. Frías, M.J. Davies, J. Rosenstock, F.C. Pérez Manghi, L. Fernández Landó, B.K. Bergman et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021)

pubmed: 34170647 doi: 10.1056/NEJMoa2107519

B. Ludvik, F. Giorgino, E. Jódar, J.P. Frias, L. Fernández Landó, K. Brown et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398, 583–598 (2021)

pubmed: 34370970 doi: 10.1016/S0140-6736(21)01443-4

D. Dahl, Y. Onishi, P. Norwood, R. Huh, R. Bray, H. Patel et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327, 534–545 (2022)

pubmed: 35133415 pmcid: 8826179 doi: 10.1001/jama.2022.0078

M.J. Davies, V.R. Aroda, B.S. Collins, R.A. Gabbay, J. Green, N.M. Maruthur et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022)

pubmed: 36148880 pmcid: 10008140 doi: 10.2337/dci22-0034

I. Lingvay, P. Sumithran, R.V. Cohen, C.W. le Roux, Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399, 394–405 (2022)

pubmed: 34600604 doi: 10.1016/S0140-6736(21)01919-X

R.V. Cohen, T.V. Pereira, C.M. Aboud, T.B.Z. Petry, J.L. Lopes Correa, C.A. Schiavon et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 155, e200420 (2020)

pubmed: 32492126 pmcid: 7270872 doi: 10.1001/jamasurg.2020.0420

M.K. Thomas, A. Nikooienejad, R. Bray, X. Cui, J. Wilson, K. Duffin et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 106, 388–396 (2021)

pubmed: 33236115 doi: 10.1210/clinem/dgaa863

T. Heise, A. Mari, J.H. DeVries, S. Urva, J. Li, E.J. Pratt et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 10, 418–429 (2022)

pubmed: 35468322 doi: 10.1016/S2213-8587(22)00085-7

C.J. Lee, H. Mao, V.T. Thieu, L.F. Landó, M.K. Thomas, Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). J. Endocr. Soc. 7, bvad056 (2023)

pubmed: 37153701 pmcid: 10157777 doi: 10.1210/jendso/bvad056

I. Lingvay, O. Mosenzon, K. Brown, X. Cui, C. O’Neill, L. Fernández Landó et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc. Diabetol. 22, 66 (2023)

pubmed: 36964557 pmcid: 10039543 doi: 10.1186/s12933-023-01797-5

B. Finan, T. Ma, N. Ottaway, T.D. Müller, K.M. Habegger, K.M. Heppner et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013)

pubmed: 24174327 doi: 10.1126/scitranslmed.3007218

J.P. Frias, M.A. Nauck, J. Van, M.E. Kutner, X. Cui, C. Benson et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392, 2180–2193 (2018)

pubmed: 30293770 doi: 10.1016/S0140-6736(18)32260-8

D. Yu, S. Shen, J. Zhang, Q. Wang, Effect of the dual glucose-dependent insulinotropic peptide/glucagon-like peptide 1 receptor agonist tirzepatide on lipid profile and waist circumference: a systematic review and meta-analysis. Clin. Ther. 45(8), 787–796 (2023)

pubmed: 37455226 doi: 10.1016/j.clinthera.2023.06.008

M. Asmar, A. Asmar, L. Simonsen, F. Dela, J.J. Holst, J. Bülow, GIP-induced vasodilation in human adipose tissue involves capillary recruitment. Endocr. Connect. 8, 806–813 (2019)

pubmed: 31063975 pmcid: 6590203 doi: 10.1530/EC-19-0144

J.M. Wilson, A. Nikooienejad, D.A. Robins, W.C. Roell, J.S. Riesmeyer, A. Haupt et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes. Metab. 22, 2451–2459 (2020)

pubmed: 33462955 pmcid: 7756479 doi: 10.1111/dom.14174

N. Sattar, D.K. McGuire, I. Pavo, G.J. Weerakkody, H. Nishiyama, R.J. Wiese et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat. Med. 28, 591–598 (2022)

pubmed: 35210595 pmcid: 8938269 doi: 10.1038/s41591-022-01707-4

J.M. Wilson, Y. Lin, M.J. Luo, G. Considine, A.L. Cox, L.M. Bowsman et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes. Metab. 24, 148–153 (2022)

pubmed: 34542221 doi: 10.1111/dom.14553

E. Gallego-Colon, W. Wojakowski, T. Francuz, Incretin drugs as modulators of atherosclerosis. Atherosclerosis 278, 29–38 (2018)

pubmed: 30248550 doi: 10.1016/j.atherosclerosis.2018.09.011

Y. Mori, T. Matsui, T. Hirano, S.-I. Yamagishi, GIP as a potential therapeutic target for atherosclerotic cardiovascular disease: a systematic review. Int. J. Mol. Sci. 21(4), 1509 (2020)

pubmed: 32098413 pmcid: 7073149 doi: 10.3390/ijms21041509

P. Rossing, M.L. Caramori, J.C.N. Chan, H.J.L. Heerspink, C. Hurst, K. Khunti et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 102, 990–999 (2022)

pubmed: 36272755 doi: 10.1016/j.kint.2022.06.013

A. Mima, H. Gotoda, R. Lee, A. Murakami, R. Akai, S. Lee, Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 Diabetes: a systematic review and meta-analysis. Metab. Open 17, 100236 (2023)

doi: 10.1016/j.metop.2023.100236

K.S. Boye, R. Mody, J. Wu, M.J. Lage, F.T. Botros, B. Woodward, Effects of dulaglutide and insulin glargine on estimated glomerular filtration rate in a real-world setting. Clin. Ther. 40, 1396–1407 (2018)

pubmed: 30093131 doi: 10.1016/j.clinthera.2018.07.002

K.S. Boye, F.T. Botros, A. Haupt, B. Woodward, M.J. Lage, Glucagon-like peptide-1 receptor agonist use and renal impairment: a retrospective analysis of an electronic health records database in the U.S. population. Diabetes Ther. 9, 637–650 (2018)

pubmed: 29460259 pmcid: 6104268 doi: 10.1007/s13300-018-0377-5